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Abstract
Nutritional support continues to receive much attention
as a possible intervention to prevent loss of lean tissue
mass, promote recovery and re-establish proper immune
function in critical care patients. Yet there remains much
controversy regarding the clinical efficacy of such
interventions. In addition to the direct effect of
nutrition in terms of micro- and macronutrient
content, nutritional formulations may exert an effect
via the physiological response to feeding. Here, we
highlight the key role of postprandial reabsorbed
bile acids in attenuating both the inflammatory
response and autophagy. These observations suggest
that not all patients would benefit from aggressive
nutritional support.
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Introduction
Three observations strongly suggest that sickness-associated
anorexia (SAA) serves an important function during an in-
fection. First, the fact that inflammatory mediators such as
interleukin-1 beta (IL-1β), IL-6 and tumour necrosis factor
(TNF) induce SAA [1] suggests that SAA is a dedicated
response enacted by the host during an infection or se-
vere trauma and not a manifestation of pathology per
se. Second, the observation that a loss of appetite mani-
fests in model organisms as well as in domestic and
companion animals strongly suggests that SAA repre-
sents an evolutionarily conserved response, indicating
that selective pressure has maintained this response on
the basis of its functional value. Thus, from an evolu-
tionary perspective, these considerations suggest that
avoiding food intake likely plays an important adaptive
function during an inflammatory response such as is in-
variably witnessed in critical care patients. Finally, it is
worth noting that inflammatory mediators antagonise
the digestive process. Cytokines such as IL-1β, IL-6 and
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TNF-α, through various mechanisms, decrease bile flow
(reviewed in [2]). Also, TNF suppresses gastric motility
through its action on the dorsal vagal complex [3]. This
illustrates that inflammatory mediators enact a range of
physiological responses intended to limit the intake of
food, strongly supporting the notion that a decrease in
feeding represents a dedicated response to inflamma-
tory mediators.
Notwithstanding these considerations, nutritional
support is administered in various contexts. The
implementation of aggressive nutritional support is
motivated by two considerations. First, it is often ar-
gued that a decrease in appetite removes the incen-
tive for foraging behaviour, thereby conserving energy
for other critical functions such as the mobilisation of
the immune response. However, nutritional support
can be administered to patients without the associ-
ated metabolic cost of gathering food. Second, activa-
tion of an inflammatory response is associated with a
remarkable increase in metabolic rate, leading to a
severe nitrogen deficit and the loss of lean tissue
mass. In addition, critically ill patients are most often
immobile which likely aggravates the catabolism of
lean tissue. Since the loss of lean mass is associated
with an increase in mortality and morbidity, nutri-
tional support not only may halt the extensive catab-
olism in critically ill patients but also may avert
malnutrition. These considerations then provide a
rational justification for implementing nutritional sup-
port in critically ill patients.
Despite these considerations, there is currently no sin-
gle study providing “unequivocal evidence that feeding
protocols targeting full-replacement nutrition early in
the course of critical illness result in clinical benefits”
[4]. A number of factors have been pointed out to con-
tribute to the controversy, including variation in the
“timing, route, and composition of nutritional interven-
tions” [5]. Another aspect seldom addressed is that
nutritional support likely exerts its effect not only
through the nutritional composition of nutrients (micro-
and macronutrients) but also through the physiological
response to food.
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Here, we argue that a major mechanism by which
nutritional support mediates its therapeutic effects re-
lates to the hormonal effect of postprandial reab-
sorbed bile acids (BAs). In particular, BAs may
attenuate the inflammatory response transcriptionally
but also could compromise lipopolysaccharide (LPS)
clearance by attenuating the expression of scavenger
receptors as well as autophagy, a cell survival re-
sponse. Emerging evidence has also implicated BAs as
transcriptional inhibitors of autophagy. Furthermore,
evidence has demonstrated that BAs alter the vascular
system, suggesting that postprandial reabsorption of
BAs may have an impact on the development of
shock. Finally, we briefly point out that nutritional
support may exert other clinically relevant effects
such as altering the microbiome. Taken together,
these observations strongly suggest that, during an in-
fection, nutritional support may curtail immunological
functions and compromise autophagy but conversely
may also prove beneficial in averting an excessive in-
flammatory response to sterile injury.
Bile acids: Modulating inflammation
Following a meal, fatty acids in the lumen of the gut
induce the release of cholecystokinin, which in turn
causes the sphincter of Oddi to relax and bile to flow
into the small intestine. Of note, the fatty acid chain
length plays a vital role in regulating the release of
cholecystokinin, and long-chain fatty acids provide a
much more pronounced release of cholecystokinin [6,
7]. Mechanistically, long-chain fatty acids activate the G
protein−coupled receptor 40 (GPR40) of cells in the
small intestine, promoting the release of cholecystokinin
[8]. Thus, fatty acid composition of enteral nutrition
directly influences BA release. In the intestine, BAs are
de-conjugated (resulting in secondary BAs) or modified
in various other ways by intestinal microbiota. Following
a meal, most of these BAs are reabsorbed: despite a large
capacity for bile synthesis, about 95% of BAs are reab-
sorbed both actively and passively, entering the mesen-
teric vein which drains into the hepatic portal vein
before finally being absorbed by liver cells in the sinus-
oidal space of the liver [9–11].
Although BAs are typically associated with diges-
tion, BAs have long been known to mediate an
anti-inflammatory effect. As an example, BAs induced
a 50% suppression of IL-6, IL-1 and TNF-α in mono-
cytes at a concentration of between 60 and 80 μmol/L
[12]. Similarly, in earlier studies, it was reported that at a
concentration of 120 μM, the secondary BA deoxycholic
acid suppressed the expression of TNF-α by 90% but only
slightly (10%) suppressed TNF-α expression at 25 μM
[13]. Even though these observations demonstrate
anti-inflammatory effects of BAs, it also is apparent that
the effects of BAs are highly dose-dependent. Thus, it
should be noted that many studies employed high
levels of BAs that may not always be applicable to all
organ systems. Normal fasting serum BA concentra-
tion is usually below 2.5 μM and may raise to a post-
prandial maximum three times above the fasting level.
However, BA concentrations are much higher within
the hepatic portal system. Fasting BA concentrations
in the venous portal system averaged 14 μM (com-
pared with the 2.4 μM in the peripheral venous sys-
tem) and exhibit a postprandial peak of 43 μM [14],
which is closer to the physiologically effective dosage
range at which inflammation is attenuated. This sug-
gests that reabsorbed BAs may primarily exert their
greatest effect on the liver.
Mechanistically, it is now well established that the
reabsorbed secondary BAs act as hormones targeting cell
surface G protein–coupled BA receptors (such as Takeda
G protein–coupled receptor 5, or TGR5) and the nuclear
receptor, farnesoid-X-receptor (FXR) [15], which also
play a role in modulating the immune system. As an
example, activation of TGR5 by BAs suppressed the of
inflammatory cytokines by LPS-challenged Kupffer cells
[16]. Correspondingly, FXR activation attenuates nuclear
factor-kappa B (NF-κB) gene transcription induced by
IL-1β in vascular smooth muscle cells [17]. FXR acti-
vation also resulted in a significant suppression of
interferon-gamma (IFNγ)-responsive genes in macro-
phages [18]. It is thus evident that activation of FXR
and TGR5 by BAs is capable of attenuating an in-
flammatory response.
BAs may also indirectly alter the inflammatory re-
sponse by compromising LPS clearance. The scaven-
ger receptor class B type I (SR-BI) plays an important
role in transporting cholesterol associated with
high-density lipoprotein (HDL) into a range of cells,
including macrophages and hepatocytes [19]. LPS also
associates with HDL, which suggests that LPS may be
cleared by the uptake of HDL through SR-BI. Indeed,
this line of reasoning is supported by findings from
Cai et al., who demonstrated that mice lacking SR-BI
exhibited decreased clearance of LPS and an accom-
panied increase in the inflammatory response to an
LPS challenge [20], highlighting the role of SR-BI in
clearing LPS. Yet it is also known that BAs, via their
function on FXR, suppress the hepatic expression of
SR-BI [21]. Thus, the postprandial reabsorption of
BAs may reduce SR-BI expression, thereby comprom-
ising the rate by which LPS is internalised and subse-
quently cleared form circulation.
Taken together, these observations demonstrate that
nutritional support may exert clinically relevant effects
through the subsequent reabsorption of BAs. The effect
of BAs may be particularly relevant in the context of
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bacterial infection: given the observation that hepatic
clearance of LPS is important in preventing excessive
inflammation [22], it is possible that nutritional support
results in elevated inflammation by compromising the
expression of SR-BI and the subsequent clearance of
LPS. Simultaneously, the anti-inflammatory effect of
BAs may result in a compromised immune response. In
this regard, it is worth noting that sepsis is often charac-
terised by a robust inflammatory response coupled with
an immune-suppressive state [23, 24]. The extent to
which the reabsorption of BAs may contribute towards
such immune dysfunction thus needs to be evaluated.
Bile acids: Modulating autophagy
Another important consequence of feeding is the sup-
pression of autophagy. Here again, the postprandial
reabsorption of BAs has been shown to attenuate au-
tophagy transcriptionally via the activation of FXR.
FXR activation suppresses the expression of various
proteins involved in autophagy by antagonising the
function of other transcription factors such as cAMP
response element-binding protein (CREB) [25]. Simi-
larly, Lee et al. [26] recently demonstrated that FXR
competes with peroxisome proliferator–activated
receptor-alpha (PPARα) for binding sites in the pro-
moter regions of various autophagic proteins with
different transcriptional outcomes: whereas PPARα
induces the expression of autophagic proteins, FXR
dramatically suppresses autophagy. Thus, by antago-
nising the function of other transcription factors such
as CREB and PPARα, FXR plays a prominent role as
a regulator of autophagy during feed-fasting cycles.
This also suggests that enteral nutrition may lead to
the suppression of autophagy as a result of FXR acti-
vation by reabsorbed BAs, consistent with previous
reports suggesting that autophagy may be attenuated
by the administration of nutritional support in rabbits
[27] and possibly also in humans [28].
Indirect evidence also suggests that the inhibition of
autophagic/lysosomal function may result in a compro-
mised ability to clear LPS during an infection. Earlier
studies have documented the localisation of LPS within
lysosomal vesicles [29]. In this regard, lysosomal vesicles
contain the enzyme acyloxyacyl hydrolase (AOAH) [30],
which is known to detoxify LPS [31], suggesting that the
autophagic machinery may play an important role in the
detoxification of LPS. This may be particularly important
during an infection when bile flow is low since most LPS
is usually removed through bile secretion [32]. In sup-
port of this view is that mice lacking the key autophagic
protein, Atg16L1, exhibit enhanced sensitivity to LPS
and an increased release of IL-1β and IL-18 [33]. Simi-
larly, in other preclinical studies using rodent models,
autophagy induction was shown to be protective in a
range of organs during sepsis [34–36], including the liver
[37, 38]. It is therefore likely that BAs curtail the clear-
ance of LPS, both by transcriptionally inactivating SR-BI
expression [21] and by preventing lysosomal detoxifica-
tion of LPS.
Bile acids as mediators of nutritional support
It is thus evident that increased BA reabsorption as a
result of nutritional support may alter the immune re-
sponse and impact on the inflammatory status of a
patient. However, BAs have also been implicated in a
range of other clinically relevant contexts. As an
nutritional support may also complicate haemodynam-
ics, not only by directly increasing blood flow towards
intestines but also indirectly through the effect of BAs
on the liver. It has long been noted that BAs cause an
increase in blood flow through the splanchnic circula-
tion [39]. In hepatic sinusoidal endothelial cells isolated
from rats, BA (25 μM taurolithocholate) activates TGR5,
resulting in increased expression of endothelial nitric
oxide (NO) synthase [40]. Given the large blood volume
of the liver, the increase in NO may lead to an increase
in blood vessel dilatation, suggesting that BAs may con-
tribute to a decrease in blood pressure.
There is also a need to evaluate the role of BAs in
other peripheral systems beyond the liver. BAs have
been shown to alter haemodynamic parameters out-
side of the enterohepatic circulation, which collect-
ively result in decreased blood pressure (reviewed in
[41]). This includes effects on the heart, as is evident
by the observation that BAs can decrease contractility
of cardiomyocytes [42], and also the vasculature, as
BAs induce vasodilatation [43]. However, most of
these studies have been conducted in the context of
cholestasis or with levels of BAs elevated above the
normal postprandial levels. Consequently, it is not to
what extent nutritional support may induce similar
effects.
Other evidence suggests that BAs may have a protect-
ive role in liver regeneration. Cholic acid has been
shown to promote liver regeneration in mice in an
FXR-dependent manner [44]. Similar findings were re-
ported by others, demonstrating that physiologically
relevant levels of BAs can promote the differentiation of
hepatocytes from mesenchymal stem cells derived from
either human or rat liver, bone marrow and umbilical
cord blood while also suppressing the expression of pro-
teins associated with fibrosis, such as COL1α2 and
α-SMA [45]. Collectively, these observations suggest that
BAs may promote liver regeneration.
Conversely, in both rats [46] and humans [47, 48],
high serum BA levels predict short-term mortality, per-
haps suggesting that BAs may have a negative impact on
patient outcome. However, both severe inflammation
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[49] and liver damage [50] are also known to increase
serum BA levels, suggesting that an increase merely
reflects disease severity rather than a directly contribut-
ing factor to pathology. Additionally, primary BAs are
modified to secondary BAs in the intestinal tract by
microbiota, altering the functions of BAs. As an
example, primary (unmodified) BAs, but not secondary
(modified) BAs, induce the expression of CXCL16 in
hepatic sinusoidal endothelial cells, resulting in
increased infiltration by natural killer T cells in the liver
[51]. This observation suggests that reabsorbed second-
ary BAs may have a clinical impact different from that of
primary BAs during cholestasis. In summary, the rela-
tionship between postprandial BAs and elevated BAs
manifesting in other disease states is unclear and war-
rants further investigation.
Taken together, these observations highlight a number
of mechanisms by which BAs mediate clinically relevant
physiological response (Fig. 1). It is thus evident that nu-
tritional support, through its effects on the release and
subsequent reabsorption of BAs, may benefit some but
not all patients. There is thus a clear need to explore the
physiological consequence of nutrition, including the
downstream effects of BAs.
Finally, although we have focused on postprandial
BAs, it is also worth noting that other elements of nutri-
tion may have adverse effects on critically ill patients. As
an example, iron is the rate-limiting element in bacterial
growth, and it is now well established that iron with-
drawal plays an adaptive immunological function di-
rected at starving bacteria of this critical element [52].
Yet it is not unusual to find enteral feeding formulations
that are supplemented with iron (for example, ferrous
sulphate). Evidence from patients with sepsis also impli-
cates a role for intestinal microbiota in the disease tra-
jectory. Evaluating metabolites in the urine of patients
with sepsis revealed an increase in ethanol as a prognos-
tic biomarker for poor outcome [53]. These authors
pointed out that, since these metabolites persisted for
24 h after hospital admission, where patients either
received a controlled diet or fasted, the ethanol must be
derived from fermentation by the microbiota. This raises
the possibility that complex starch such as maltodextrin,
a major component of enteral nutritional formulas, in
fact provides fermentable substrates that increase etha-
nol production by intestinal microbiota. These observa-
tions suggest that nutritional support may have clinically
relevant consequences that extend beyond addressing
the nutritional need of the patient.
Conclusion
It is thus clear that elevation of BAs resulting from nutri-
tional support may alter autophagy and inflammation and
possibly impact the development of shock. Collectively,
Fig. 1 Bile acids (BAs) released in response to food are modified by intestinal microbiota before being reabsorbed. Reabsorbed BAs may exert a
number of effects on the liver, including attenuating the inflammatory response, diminishing autophagic activity and inducing nitric oxide–mediated
vasodilatation. Since BAs are effectively reabsorbed, systemic levels may be much lower and the effects of BAs may be less pronounced. Abbreviation:
LPS lipopolysaccharide
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these observations suggest that nutritional support may be
more beneficial in patients where an immediate threat of
infection is not present or where an anti-inflammatory ef-
fect is pursued. However, it is not clear how elevated BAs
after a meal and the elevation of BAs in other disease states
(for example, inflammation-induced cholestasis) are func-
tionally related. There is also a need for more targeted
studies aimed at elucidating the direct effect of BAs and
the possible therapeutic application of BA supplementation
in critically ill patients. Finally, the potential impact of post-
prandial reabsorbed BAs highlights an important consider-
ation: nutritional support may exert effects that extend
beyond the nutrient needs of the patient.
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